Literature DB >> 33492533

Inflammatory Bowel Disease Does Not Impact Mortality but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction.

Preetika Sinh1,2, James H Tabibian3, Prachi S Biyani4, Kathan Mehta5, Emad Mansoor2, Edward V Loftus6, Maneesh Dave7.   

Abstract

BACKGROUND AND AIM: Inflammatory bowel diseases (IBD) have been associated with increased risk of cardiovascular events. We aimed to investigate the outcomes of myocardial infarction (MI) in patients with IBD.
METHODS: We performed a cross-sectional study utilizing data from the Nationwide Inpatient Sample from the years 1998 to 2010. ICD-9-CM codes were used to identify patients with Crohn's disease (CD) (555.X), ulcerative colitis (UC) (556.X), and acute MI (410.X). Outcomes in patients with MI with and without IBD were compared. Univariate analysis was performed. Multivariate logistic regression was used to determine the effect of UC and CD on in-hospital MI mortality after adjusting for confounders.
RESULTS: A total of 2,629,161 MI, 3,607 UC and 3784 CD patients were analyzed. UC (odds ratio [OR], 1.12; 95% CI 0.98-1.29) and CD (OR 0.99; 95% CI 0.86-1.15) did not affect in-hospital mortality in patients with MI. There was no difference between in-hospital mortality in patients with MI with or without UC (7.75% vs. 7.05%; p = 0.25) or in patients with MI with or without CD (6.50% vs. 6.59%; p = 0.87). The length of stay (LOS) was higher in IBD patients and total charges were statistically higher in patients with UC as compared to non-IBD patients ($65,182 vs. $53,542; p < 0.001).
CONCLUSIONS: This study shows that IBD does not impact in-hospital mortality from MI. However, patients with MI with IBD have longer LOS. Patients with UC have higher total hospitalization charges than patients with MI without IBD. Further prospective studies are needed to assess the outcomes of MI in IBD patients.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Cardiovascular risk; Inflammatory bowel disease; Mortality; Myocardial infarction

Mesh:

Year:  2021        PMID: 33492533     DOI: 10.1007/s10620-020-06818-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Authors:  O Ahlehoff; G H Gislason; M Charlot; C H Jørgensen; J Lindhardsen; J B Olesen; S Z Abildstrøm; L Skov; C Torp-Pedersen; P R Hansen
Journal:  J Intern Med       Date:  2010-11-29       Impact factor: 8.989

2.  Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases.

Authors:  Nghia H Nguyen; Lucila Ohno-Machado; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2018-03-19       Impact factor: 5.325

3.  Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.

Authors:  Michael D Kappelman; Erzsebet Horvath-Puho; Robert S Sandler; David T Rubin; Thomas A Ullman; Lars Pedersen; John A Baron; Henrik T Sørensen
Journal:  Gut       Date:  2011-02-21       Impact factor: 23.059

4.  Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.

Authors:  Julien Kirchgesner; Laurent Beaugerie; Fabrice Carrat; Nynne Nyboe Andersen; Tine Jess; Michaël Schwarzinger
Journal:  Gut       Date:  2017-06-24       Impact factor: 23.059

5.  Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.

Authors:  Christina Charles-Schoeman; Pierre Wicker; Miguel A Gonzalez-Gay; Mary Boy; Andrea Zuckerman; Koshika Soma; Jamie Geier; Kenneth Kwok; Richard Riese
Journal:  Semin Arthritis Rheum       Date:  2016-06-02       Impact factor: 5.532

6.  Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.

Authors:  Christine Rungoe; Saima Basit; Mattis Flyvholm Ranthe; Jan Wohlfahrt; Ebbe Langholz; Tine Jess
Journal:  Gut       Date:  2012-09-08       Impact factor: 23.059

7.  The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; James F Blanchard
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12-11       Impact factor: 11.382

Review 8.  Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Harkirat Singh; Edward V Loftus; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-24       Impact factor: 11.382

9.  Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study.

Authors:  Søren Lund Kristensen; Ole Ahlehoff; Jesper Lindhardsen; Rune Erichsen; Gunnar Vagn Jensen; Christian Torp-Pedersen; Ole Haagen Nielsen; Gunnar Hilmar Gislason; Peter Riis Hansen
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

10.  Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center.

Authors:  S Santilli; D R Kast; I Grozdev; L Cao; R L Feig; J B Golden; S M Debanne; R C Gilkeson; C E Orringer; T S McCormick; N L Ward; K D Cooper; N J Korman
Journal:  J Transl Med       Date:  2016-07-22       Impact factor: 5.531

View more
  1 in total

Review 1.  Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention.

Authors:  Alina Ecaterina Jucan; Otilia Gavrilescu; Mihaela Dranga; Iolanda Valentina Popa; Bogdan Mircea Mihai; Cristina Cijevschi Prelipcean; Cătălina Mihai
Journal:  Life (Basel)       Date:  2022-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.